Lomenaz 1000mg

Lomenaz 1000mg
17 May

Lomenaz 1000mg

Gynecology Drugs
  • The active component of LOMENAZ® is Fenticonazole nitrate that is an imidazole antifungal  agent with antimicrobial activity against some gram-Positive bacteria and is therefore indicated in mycosis associated with bacterial super infections .
  • Fenticonazole nitrate exerts fungistatic and fungicidal actions on dermatophytes (responsible for most mycotic skin infections) pathogenic yeasts, dimorphous fungi and moulds.
  • LOMENAZ® is active, both in vitro and in vivo, against trichomonas vaginalis .

Ingredients

  • 1000mg

Indecation

  • LOMENAZ® are indicated for the local treatment of :
  • Trichomonas vaginalis .
  • Vaginal infections sustained by mixed forms of Trichomonas vaginalis and candida albicans .
  • Genital candidiasis (vulvovaginitis, colpitis, infectious fluor) .

Dosage & Administration

  • LOMENAZ® 1000 mg vaginal ovule : Trichomonas or mixed ( trichomonas and candida albicans ) vaginal infections : One 1000 mg ovule followed by a second administration 24 hours later, when necessary .
  • Candida albicans infections : One 1000 mg ovule followed by a second administration in the evening . Should the symptoms persist, a second administration may be repeated after three days .
  • LOMENAZ® 600 mg vaginal ovule: One 600 mg ovule at bedtime followed by a second administration 3 days later if symptoms persist.
  • The ovules must be introduced deep into the vagina and pushed well up to the fornix.
  • LOMENAZ® vaginal Cream : One applicator full (5 g) is administered into the vagina morning and before going to bed for three days.
  • Each ovule of LOMENAZ® vaginal ovule contains :
    • Fenticonazole nitrate 600 mg Or 1000 mg
  • Each tube of LOMENAZ® vaginal Cream contains :
    • Fenticonazole nitrate 2%a

Hypersensitivity to Fenticonazole nitrate .

  • Due to the limited systemic availability after vaginal application, clinically relevant interactions occur very rarely.
  • Contact should be avoided between latex products (such as contraceptive diaphragms, condoms) and LOMENAZ®, since intra vaginal preparations of fenticonazole may damage the latex .
  • Use during pregnancy : Although transcutaneous and vaginal absorption of Fenticonazole is very poor, use of the preparation is not recommended in pregnancy .
  • Use during lactation :It is not known whether intravaginal Fenticonazole is excreted in breast milk.
  • However, problems during lactation have not been documented, caution should be considered.
  • LOMENAZ® are usually well tolerated . Some adverse reactions have rarely been reported including local irritation or sensitivity include mild burning sensation, erythema, and vaginal itching. Should more persist irritation occur or resistant micro-organism develop, suspend the treatment and seek the doctor’s advice.
  • Due to LOMENAZ® poor absorption, no systemic effects should occur, provided the above instructions are carefully observed.
  • If local irritation and hypersensitivity reactions occur, treatment should be discontinued .
  • General hygienic measures should be observed to control sources of infection or reinfection.
  • Appropriate therapy is indicated when the sexual partner is also infected .
  • LOMENAZ® 600 mg ovule: Pack of one ovule.
  • LOMENAZ®1000 mg ovule: Pack of one ovule.
  • LOMENAZ® Vaginal cream: Tube of 30 g with applicator.

Store in a dry place away from light at a temperature below 30 0C .